Investigators Highlight Improvements in Immune and Endocrine Therapies for Breast Cancer

Breast oncologists recap findings from the 2022 San Antonio Breast Cancer Symposium. Sasha E. Stanton, MD, PhD, says that for patients
with hormone receptor–positive disease finding the best immunotherapeutic choice can present a challenge. Rupert Bartsch, MD, highlights findings from the phase 2 RIGHT Choice study (NCT03839823), which demonstrated promise with ribociclib (Kisqali) plus goserelin
acetate plus hormonal therapy among patients with advanced/metastatic disease. Erika P. Hamilton, MD, reviews exciting novel endocrine
therapies that may soon play a role.

TO WATCH, VISIT bit.ly/3ITTDtD.